Efficacy and limitations of continuous intravenous epoprostenol therapy for idiopathic pulmonary arterial hypertension in Japanese children

Circulation Journal

Volumn 71, Issue 11, 2007, Pages 1785-1790

  Nakayama, Tomotaka ^a   Shimada, Hiromitsu ^a   Takatsuki, Shinichi ^a   Hoshida, Hiroshi ^a   Ishikita, Takashi ^a   Matsuura, Hiroyuki ^a   Saji, Tsutomu ^a  

^a TOHO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Children; Epoprostenol; Long term outcome; Pulmonary arterial hypertension (PAH)

Indexed keywords

BERAPROST; PROSTACYCLIN; SILDENAFIL;

ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; INFANT; LUNG ARTERY PRESSURE; MALE; OUTCOME ASSESSMENT; PULMONARY HYPERTENSION; SURVIVAL RATE; WORLD HEALTH ORGANIZATION;

ADOLESCENT; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CHILD; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; EPOPROSTENOL; HUMANS; HYPERTENSION, PULMONARY; INFANT; INFANT, NEWBORN; INFUSIONS, INTRAVENOUS; JAPAN; NATRIURETIC PEPTIDE, BRAIN; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 36949017768     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.71.1785     Document Type: Article

References (28)

1. Barst RJ, Rubin LJ, McGoon MD, Caldwell EJ, Long WA, Levy PS. Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin. Ann Intern Med 1994; 121: 409-415.
2. Barst RJ, Rubin LJ, Long WA, McGoon MD, Rich S, Badesch DB, et al. The Primary Pulmonary Hypertension Study Group: A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med 1996; 334: 296-302.
3. Higenbottam T, Butt AY, McMahon A, Westerbeck R, Sharples L. Long-term intravenous prostaglandin (epoprostenol or iloprost) for treatment of severe pulmonary hypertension. Heart 1998; 80: 151-155.
4. McLaughlin VV, Genthner DE, Panella MM, Rich S. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. N Engl J Med 1998; 338: 273-277.
5. Conte JV, Gaine SP, Orens JB, Harris T, Rubin LJ. The influence of continuous intravenous prostacyclin therapy for primary pulmonary hypertension on the timing and outcome of transplantation. J Heart Lung Transplant 1998; 17: 679-685.
6. Robbins IM, Christman BW, Newman JH, Matlock R, Loyd JE. A survey of diagnostic practices and the use of epoprostenol in patients with primary pulmonary hypertension. Chest 1998; 114: 1269-1275.
7. Ziesche R, Petkov V, Wittmann K, Kopatschka J, Stiebellehner L, Schenk P, et al. Treatment with epoprostenol reverts nitric oxide non-responsiveness in patients with primary pulmonary hypertension. Heart 2000; 83: 406-409.
8. Barst RJ, Maislin G, Fishman AP. Vasodilator therapy for primary pulmonary hypertension in children. Circulation 1999; 99: 1197-1208.
9. Wax D, Garofano R, Barst RJ. Fffects of long-term infusion of prostacyclin on exercise performance in patients with primary pulmonary hypertension. Chest 1999; 116: 914-920.
10. McLaughlin VV, Shillington A, Rich S. Survival in primary pulmonary hypertension: The impact of epoprostenol therapy. Circulation 2002; 106: 1477-1482.
11. Kuhn KP, Byrne DW, Arbogast PG, Doyle TP, Loyd JE, Robbins IM. Outcome in 91 consecutive patients with pulmonary arterial hypertension receiving epoprostenol. Am J Respir Crit Care Med 2003; 167: 580-586.
12. Sitbon O, Humbert M, Nunes H, Parent F, Garcia G, Herve P, et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: Prognostic factors and survival. J Am Coll Cardiol 2002; 40: 780-788.
13. Yung D, Widlitz AC, Rosenzweig EB, Kerstein D, Maislin G, Barst RJ. Outcomes in children with idiopathic pulmonary arterial hypertension. Circulation 2004; 110: 660-665.
14. Haworth SG. Primary pulmonary hypertension in childhood. Arch Dis Child 1998; 79: 452-455.
15. Nagaya N, Nishikimi T, Uematsu M, Satoh T, Kyotani S, Sakamaki F, et al. Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. Circulation 2000; 102: 865-870.
16. Ationu A, Carter ND. Brain and atrial natriuretic peptide plasma concentrations in normal healthy children. Br J Biomed Sci 1993; 50: 92-95.
17. Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002; 346: 896-903.
18. Rosenzweig EB, Ivy DD, Widlitz A, Doran A, Claussen LR, Yung D, et al. Effects of long-term bosentan in children with pulmonary arterial hypertension. J Am Coll Cardiol 2005; 46: 697-704.
19. Wilkens H, Guth A, Konig J, Forestier N, Cremers B, Hennen B, et al. Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension. Circulation 2001; 104: 1218-1222.
20. Sastry BK, Narasimhan C, Reddy NK, Raju BS. Clinical efficacy of sildenafil in primary pulmonary hypertension: A randomized, placebo-controlled, double blind, crossover study. J Am Coll Cardiol 2004; 43: 1149-1153.
21. Kataoka M, Satoh T, Manabe T, Anzai T, Yoshikawa T, Mitamura H, et al. Oral sildenafil improves primary pulmonary hypertension refractory to epoprostenol. Circ J 2005; 69: 461-465.
22. Sasayama S, Kunieda T, Tomoike H, Matsuzaki M, Shirato K, Kuriyama T, et al. Effects of the endothelin receptor antagonist on hemodynamics, symptoms and functional capacity in Japanese patients. Circ J 2005; 69: 131-137.
23. Stiebellehner L, Petkov V, Vonbank K, Funk G, Schenk P, Ziesche R. Long-term treatment with oral sildenafil in addition to continuous IV epoprostenol in patients with pulmonary arterial hypertension. Chest 2002; 123: 1293-1295.
24. Ivy DD, Doran A, Claussen L, Bingaman D, Yetman A. Weaning and discontinuation of epoprostenol in children with idiopathic pulmonary arterial hypertension receiving concomitant bosentan. Am J Cardiol 2004; 93: 943-946.
25. Kim NH, Channick RN, Rubin LJ. Successful withdrawal of long-term epoprostenol therapy for pulmonary arterial hypertension. Chest 2003; 124: 1612-1615.
26. Rich S, McLaughlin VV. The effects of chronic prostacyclin therapy on cardiac output and symptoms in primary pulmonary hypertension. J Am Coll Cardiol 1999; 34: 1184-1187.
27. Wasserman K, Oudiz R. Overdosing with prostacyclin in primary pulmonary hypertension. J Am Coll Cardiol 2000; 35: 1995-1996.
28. Marcus JT, Noordegraaf AV, Roeleveld RJ, Postmus PE, Heethaar RM, Rossum VR, et al. Impaired left ventricular filling due to right ventricular pressure overload in primary pulmonary hypertension. Chest 2001; 119: 1761-1765.